NVNO
enVVeno Medical Corporation
Medical - Devices
Market Cap$7M
5Y Perf.+22.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NVNO vs TELA
Revenue, margins, valuation, and 5-year total return — side by side.
TELA
TELA Bio, Inc.
Medical - Devices
Market Cap$41M
5Y Perf.-92.6%
NVNO vs TELA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NVNO | TELA |
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $7M | $41M |
| Revenue (TTM) | $0.00 | $77M |
| Net Income (TTM) | $-19M | $-39M |
| Gross Margin | — | 67.2% |
| Operating Margin | — | -46.0% |
| Total Debt | $700K | $43M |
| Cash & Equiv. | $3M | $53M |
NVNO vs TELA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NVNO
TELA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| enVVeno Medical Cor… (NVNO) | 100 | 122.0 | +22.0% |
| TELA Bio, Inc. (TELA) | 100 | 7.4 | -92.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NVNO vs TELA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TELA leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. enVVeno Medical Corporation is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
NVNO
enVVeno Medical Corporation
The Growth Play
NVNO is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- EPS growth 97.9%
- Lower volatility, beta 2.02, Low D/E 2.6%, current ratio 13.58x
- 2.3% margin vs TELA's -50.6%
Best for: growth exposure and sleep-well-at-night
TELA
TELA Bio, Inc.
The Income Pick
TELA carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.33
- -92.4% 10Y total return vs NVNO's -92.4%
- Beta 0.33, current ratio 5.01x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TELA | 18.6% revenue growth vs NVNO's 12.0% |
| Quality / Margins | NVNO | 2.3% margin vs TELA's -50.6% |
| Stability / Safety | TELA | Beta 0.33 vs NVNO's 2.02 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NVNO | +173.8% vs TELA's +3.0% |
| Efficiency (ROA) | TELA | -53.1% ROA vs NVNO's -60.4%, ROIC -151.6% vs -47.3% |
NVNO vs TELA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2019
Segment breakdown not available.
NVNO vs TELA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNVNOLAGGINGTELA
TELATELA Bio, Inc.
0leads
NVNOenVVeno Medical Corpo…
2leads
6 Total Categories
CATEGORYLEADERvs TELAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NVNO1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
NVNO5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NVNO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TELA and NVNO operate at a comparable scale, with $77M and $0 in trailing revenue.
| Metric | NVNOenVVeno Medical C… | TELATELA Bio, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $77M |
| EBITDAEarnings before interest/tax | -$20M | -$34M |
| Net IncomeAfter-tax profit | -$19M | -$39M |
| Free Cash FlowCash after capex | -$15M | -$32M |
| Gross MarginGross profit ÷ Revenue | — | +67.2% |
| Operating MarginEBIT ÷ Revenue | — | -46.0% |
| Net MarginNet income ÷ Revenue | — | -50.6% |
| FCF MarginFCF ÷ Revenue | — | -40.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +9.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +97.8% | +54.8% |
NVNO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — NVNO and TELA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | NVNOenVVeno Medical C… | TELATELA Bio, Inc. |
|---|---|---|
| Market CapShares × price | $7M | $41M |
| Enterprise ValueMkt cap + debt − cash | $4M | $32M |
| Trailing P/EPrice ÷ TTM EPS | -0.30x | -0.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.59x |
| Price / BookPrice ÷ Book value/share | 0.22x | 1.02x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — NVNO and TELA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — NVNO and TELA each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
NVNO delivers a -66.4% return on equity — every $100 of shareholder capital generates $-66 in annual profit, vs $-3 for TELA. NVNO carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to TELA's 1.51x. On the Piotroski fundamental quality scale (0–9), TELA scores 4/9 vs NVNO's 1/9, reflecting mixed financial health.
| Metric | NVNOenVVeno Medical C… | TELATELA Bio, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -66.4% | -2.7% |
| ROA (TTM)Return on assets | -60.4% | -53.1% |
| ROICReturn on invested capital | -47.3% | -151.6% |
| ROCEReturn on capital employed | -59.5% | -51.4% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 1.51x |
| Net DebtTotal debt minus cash | -$2M | -$10M |
| Cash & Equiv.Liquid assets | $3M | $53M |
| Total DebtShort + long-term debt | $700,000 | $43M |
| Interest CoverageEBIT ÷ Interest expense | — | -6.99x |
Evenly matched — NVNO and TELA each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
NVNO leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NVNO five years ago would be worth $18,790 today (with dividends reinvested), compared to $800 for TELA. Over the past 12 months, NVNO leads with a +173.8% total return vs TELA's +3.0%. The 3-year compound annual growth rate (CAGR) favors NVNO at 39.8% vs TELA's -53.1% — a key indicator of consistent wealth creation.
| Metric | NVNOenVVeno Medical C… | TELATELA Bio, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +2740.0% | -10.5% |
| 1-Year ReturnPast 12 months | +173.8% | +3.0% |
| 3-Year ReturnCumulative with dividends | +173.1% | -89.7% |
| 5-Year ReturnCumulative with dividends | +87.9% | -92.0% |
| 10-Year ReturnCumulative with dividends | -92.4% | -92.4% |
| CAGR (3Y)Annualised 3-year return | +39.8% | -53.1% |
NVNO leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NVNO and TELA each lead in 1 of 2 comparable metrics.
Risk & Volatility
TELA is the less volatile stock with a 0.33 beta — it tends to amplify market swings less than NVNO's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVNO currently trades 76.5% from its 52-week high vs TELA's 46.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NVNOenVVeno Medical C… | TELATELA Bio, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.02x | 0.33x |
| 52-Week HighHighest price in past year | $13.00 | $2.20 |
| 52-Week LowLowest price in past year | $0.30 | $0.50 |
| % of 52W HighCurrent price vs 52-week peak | +76.5% | +46.4% |
| RSI (14)Momentum oscillator 0–100 | 41.2 | 67.4 |
| Avg Volume (50D)Average daily shares traded | 13K | 191K |
Evenly matched — NVNO and TELA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NVNOenVVeno Medical C… | TELATELA Bio, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NVNO leads in 2 of 6 categories — strongest in Income & Cash Flow and Total Returns. 3 categories are tied.
Best OverallenVVeno Medical Corporation (NVNO)Leads 2 of 6 categories
Loading custom metrics...
NVNO vs TELA: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — NVNO or TELA?
Over the past 5 years, enVVeno Medical Corporation (NVNO) delivered a total return of +87.
9%, compared to -92. 0% for TELA Bio, Inc. (TELA). Over 10 years, the gap is even starker: TELA returned -92. 4% versus NVNO's -92. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — NVNO or TELA?
By beta (market sensitivity over 5 years), TELA Bio, Inc.
(TELA) is the lower-risk stock at 0. 33β versus enVVeno Medical Corporation's 2. 02β — meaning NVNO is approximately 510% more volatile than TELA relative to the S&P 500. On balance sheet safety, enVVeno Medical Corporation (NVNO) carries a lower debt/equity ratio of 3% versus 151% for TELA Bio, Inc. — giving it more financial flexibility in a downturn.
03Which is growing faster — NVNO or TELA?
On earnings-per-share growth, the picture is similar: enVVeno Medical Corporation grew EPS 97.
9% year-over-year, compared to 34. 8% for TELA Bio, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — NVNO or TELA?
enVVeno Medical Corporation (NVNO) is the more profitable company, earning 0.
0% net margin versus -54. 6% for TELA Bio, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVNO leads at 0. 0% versus -49. 2% for TELA. At the gross margin level — before operating expenses — TELA leads at 67. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — NVNO or TELA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is NVNO or TELA better for a retirement portfolio?
For long-horizon retirement investors, TELA Bio, Inc.
(TELA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 33)). enVVeno Medical Corporation (NVNO) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TELA: -92. 4%, NVNO: -92. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between NVNO and TELA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NVNO is a small-cap quality compounder stock; TELA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.